Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

NCT ID: NCT01784978

Last Updated: 2017-10-02

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-12
• Study Completion Date: 2017-05-08

Brief Summary

The objective of this study is to assess the progression-free survival, of patients who receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a first line treatment followed by everolimus when progression occurs.

Detailed Description

This is an open-label, randomized phase II study to investigate the feasibility of alternating cycles of treatment with sunitinib and everolimus compared to sequential treatment of sunitinib followed by everolimus.

The study population consists of adult patients (over 18 years old) with clear cell mRCC (Metastatic Renal Cell Cancer) who have not received prior therapy for their metastatic disease.

The purpose of the study is to determine the progression free survival, feasibility and safety profile of the experimental arm compared to standard of care.

In the experimental arm alternating treatment will consist of repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer. The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.

Conditions

Metastatic Renal Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Rotational arm

Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.

Group Type: EXPERIMENTAL

Sunitinib

Intervention Type: DRUG

50 mg pd

Everolimus

Intervention Type: DRUG

10 mg pd

Sequential arm

The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.

Group Type: ACTIVE_COMPARATOR

Sunitinib

Intervention Type: DRUG

50 mg pd

Everolimus

Intervention Type: DRUG

10 mg pd

Interventions

Sunitinib

50 mg pd

Intervention Type: DRUG

Everolimus

10 mg pd

Intervention Type: DRUG

Other Intervention Names

SUTENT; AFINITOR

Eligibility Criteria

Inclusion Criteria

• Renal cell carcinoma with a predominant clear cell component confirmed by histology.
• Advanced disease: metastatic AND, not suitable for resection
• Male or female, aged 18 years or older
• ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1
• Low or intermediate MSKCC (Memorial Sloan Kettering Cancer Center) prognostic risk score,i.e. no more than 2 of the following:

• Karnofsky performance status (<80%)
• Low serum hemoglobin (≤ 13 g/dL for males and ≤ 11.5 g/dL for females)
• High corrected serum calcium (≥ 10 mg/dL)
• Target and/or non-target lesions according to RECIST 1.1 ( Response Evaluation Criteria in Solid Tumors)
• Expected survival of at least 3 months.
• No prior systemic treatment. But adjuvant treatment is ok if stopped from ≥ 24 months
• Adequate bone marrow function as shown by:
• Adequate liver function as shown by:
• Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN (upper limit of normal)
• Left ventricular ejection fraction ≥55% on gated cardiac blood pool scan, or normal left ventricular function and fractional shortening on echocardiogram (according to institutional limits).
• SBP (systolic blood pressure) ≤140mmHg and DBP (diastolic blood pressure)

• 90mmHg (it is acceptable to initiate antihypertensive treatment prior to registration to achieve these goals).
• Able to commence treatment within 7 days of registration.
• Willing and able to comply with follow-up and all other protocol requirements.
• Written informed consent

Exclusion Criteria

• Prior treatment with VEGF-targeting agents or multi-kinase inhibitors or mTOR-targeting agents
• Active central nervous system metastases.
• Other malignancy diagnosed within the last 5 years, except the following if adequately treated: superficial squamous cell carcinoma or basal cell carcinoma of skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.
• Treatment with an investigational agent in the last 4 w.
• Known to be HIV positive.
• Evidence of chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus (HCV)
• Clinically significant heart disease (NYHA Class III or IV)
• History of hypertension requiring hospitalization.
• Other serious illnesses,
• Immunotherapy or chemotherapy in the last 4 w (6 weeks for nitrosoureas)
• Major surgery in the last 4 w, or planned in the next 6 w
• Radiation therapy in the last 2 w, or planned in the next 6 w
• NCI CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0 grade 3 or worse hemorrhage in last 4 w.
• Any of the following in the last year: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
• Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
• Ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 grade ≥2, atrial fibrillation of any grade, or prolongation of the corrected QT interval (QTc) to >450 msec for males or >470 msec for females
• Uncontrolled diabetes as defined by fasting serum glucose >1.5 X ULN.
• Pregnancy,lactation. Inadequate contraception.
• Known allergy or hypersensitivity to everolimus, sunitinib or iodine.
• Medical or psychiatric condition that compromises the patient's ability to give informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

Pivotal S.L.

INDUSTRY

Sponsor Role: collaborator

Associació per a la Recerca Oncologica, Spain

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joaquim Bellmunt, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Associacio Per la Recerca Oncológica (APRO)

Locations

Hopital Bordeaux University

Bordeaux, , France

ALEXANDRA General Hospital of Athens

Athens, , Greece

Hospital Marqués de Valdecilla

Santander, Cantabria, Spain

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, Spain

Hospital del Mar

Barcelona, , Spain

Hospital Universitario 12 de Octubre

Madrid, , Spain

Hospital Clínico San Carlos

Madrid, , Spain

Clara Campal. Hospital Sanchinarro

Madrid, , Spain

Hospital Universitario Virgen de la Victoria

Málaga, , Spain

Hospital General Universitario de Valencia

Valencia, , Spain

Countries

France; Greece; Spain

References

Rodriguez-Vida A, Bamias A, Esteban E, Saez MI, Lopez-Brea M, Castellano D, Caballero C, Gonzalez-Larriba JL, Calvo E, Macia S, Ravaud A, Bellmunt J. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). BJU Int. 2020 Nov;126(5):559-567. doi: 10.1111/bju.15165. Epub 2020 Aug 2.

Reference Type: DERIVED

PMID: 32654362 (View on PubMed)

Other Identifiers

SUNRISES STUDY (CRAD001LIC34T)

Identifier Type: -

Identifier Source: org_study_id